Canadian Cancer Trials Group Bulletins


Dr. Kim Chi Incoming Chair of the IND Committee

As many of you will know, the IND Committee has a systematic process of identifying leadership of the IND Committee. The process begins with selection of an Incoming Chair who spends a two-year term in this position prior to becoming the Chair. After serving as Chair for 2 years, this individual then becomes the Past Chair for an additional term of 2 years. In April of this year, Dr. Hal Hirte from Hamilton, Ontario completed his term as Incoming Chair and became Chair of the IND Committee. Dr. Karen Gelmon from the British Columbia Cancer Agency completed her term as Chair and became the Past Chair.

It is a privilege to now welcome Dr. Kim Chi from the BCCA to the position of Incoming Chair. Kim is a Canadian leader in drug development processes for cancer therapeutics and he has also been very active with leadership roles within our IND and Genitourinary Committees. Please join me in welcoming Kim to this new role. We look forward to working with him and thank him for taking on these leadership responsibilities.